Prevalence and characteristics of naturally occurring sofosbuvir resistance-associated variants in patients with hepatitis C virus genotype 1b infection
详细信息 查看全文
- 作者：Jun Ito ; Goki Suda ; Yoshiya Yamamoto ; Atsushi Nagasaka ; Ken Furuya ; Kenichi Kumagai ; Hideaki Kikuchi ; Takuto Miyagishima ; Tomoe Kobayashi ; Megumi Kimura ; Kazushi Yamasaki ; Machiko Umemura ; Takaaki Izumi ; Seiji Tsunematsu ; Fumiyuki Sato ; Yoko Tsukuda ; Katsumi Terashita ; Masato Nakai ; Takuya Sho ; Mitsuteru Natsuizaka ; Kenichi Morikawa ; Koji Ogawa ; Naoya Sakamoto and for the NORTE Study Group
- 刊名：Hepatology Research
- 出版年：2016
- 出版时间：December 2016
- 年：2016
- 卷：46
- 期：13
- 页码：1294-1303
- 全文大小：304K
- ISSN：1872-034X
文摘
Sofosbuvir (SOF), a nucleotide analog pro-drug, targets hepatitis C virus (HCV) NS5B polymerase and shows potential for treating HCV infection, given its high efficacy and good barrier to resistance. However, in addition to the rare resistant-associated variant (RAV) of non-structural protein NS5B S282T, several new potential RAVs of SOF have been reported, especially related to HCV genotype 1b. However, the prevalence and characteristics of these RAVs have not been clarified.